Thromb Haemost 1986; 56(03): 411-414
DOI: 10.1055/s-0038-1661693
Original Article
Schattauer GmbH Stuttgart

Measurement of Urokinase-Type Plasminogen Activator (u-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies

V Darras
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
M Thienpont
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
D C Stump
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
D Collen
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 03 February 1986

Accepted after revision 11 November 1986

Publication Date:
18 July 2018 (online)

Summary

An enzyme-linked immunosorbent assay (ELISA) for the measurement of urokinase-type plasminogen activator (u-PA) was developed. Three murine monoclonal antibodies to single chain urokinase-type plasminogen activator (scu-PA) were isolated and shown to react with non-overlapping epitopes in scu-PA. Two of the three antibodies were coated onto microtiter plates and bound u-PA was quantitated with the third antibody conjugated to horseradish peroxidase. The assay was equally sensitive to Mr 54,000 u-PA in the single chain or two-chain form but did not respond to Mr 33,000 urokinase. The lower limit of sensitivity of the assay was 0.1 ng/ml in buffer and 1 ng/ml in plasma. Coefficients of variation of the assay at physiological levels of u-PA were 6.5 percent within assays and 13 percent between assays. The level of u-PA in normal resting plasma was 1.9 ± 0.66 ng/ml (mean ± SD, n = 54). The assay can be performed within one working day and provides an efficient, reproducible, and stable means for the measurement of u-PA in biological fluids. As such it may facilitate physiological and pharmacological studies of urokinase-type plasminogen activators in man.

 
  • References

  • 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
  • 2 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
  • 3 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin J Biol Chem 1982; 257: 2912-2919
  • 4 Lijnen HR, Zamarron C, Blaber M, Winkler M, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 1986; 261: 1253-1258
  • 5 Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J Biol Chem 1986; 261: 1267-1273
  • 6 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
  • 7 Van de Werf F, Nobuhara M, Collen DE. Coronary thrombolysis with human single chain, urokinase-type plasminogen activator (prourokinase) in patients with acute myocardial infarction. Ann Int Med 1986; 10: 345-348
  • 8 Collen D. Human tissue-type plasminogen activator: from the laboratory to the bedside. Circulation 1985; 72: 18-20
  • 9 Vetterlein D, Bell TE, Young PL, Roblin R. Immunological quantitation and immunoadsorption of urokinase-like plasminogen activators secreted by human cells. J Biol Chem 1980; 255: 3665-3672
  • 10 Hérion P, Portetelle D, Franssen JD, Urbain J, Bollen A. Solid-phase enzyme immunoassay of urokinase using monoclonal antibodies. Bioscience Rep 1983; 3: 381-388
  • 11 Huber K, Kirchheimer J, Binder BR. Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen. J Lab Clin Med 1984; 103: 684-694
  • 12 Stump DC, Lijnen HR, Collen D. Purification and characterization of single chain urokinase-type plasminogen activator from human cell cultures. J Biol Chem 1986; 261: 1274-1278
  • 13 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
  • 14 Kearney JF, Radbruch A, Liesegang B, Rajewski K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979; 123: 1548-1550
  • 15 Galfré G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 1981; 73: 3-46
  • 16 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sephar-ose. Immunochemistry 1978; 15: 429-436
  • 17 Ouchterlony O. Diffusion in gel methods for immunological analysis. Prog Allergy 1958; 5: 1-78
  • 18 Nakane PA, Kawaoi A. Peroxidase labeled antibody. A new method of conjugation. J Histochem Cytochem 1974; 22: 1084-1091
  • 19 Kirchheimer J, Binder B. Urokinase antigen in plasma: age and sex dependent variations. Thromb Res 1984; 36: 643-646
  • 20 Kirchheimer JC, Huber K, Binder BR. Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma. Thromb Haemostas 1985; 54: 617-618
  • 21 Tissot JD, Schneider P, Ruegg M, Kruithof EK O, Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest 1982; 70: 1320-1323
  • 22 Stump DC, Thienpont M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem 1986 (in press)